Relapsed or Refractory High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with or without NPM1 Mutation research hub

A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)

This study is looking at a new drug, RVU120, for adults with specific types of blood cancer that have come back or not responded to previous treatments. It aims to see how well the drug works to put the cancer into remission.